Industries

Roche’s enicepatide adds diabetes results as Phase 3 trials recruit

The Tip Desk · September 23, 2026 · 3 min read

A 48-week Phase 2 readout broadens the obesity program’s evidence, while longer pivotal trials and a combination study address separate questions.

Enicepatide connects several names in one development story: CT-388, RO7795068 and RG6640. Roche's current program includes weekly injected treatment in obesity and a study in people with type 2 diabetes. The compound remains investigational.

On September 22, Roche reported Phase 2 results in 447 adults with type 2 diabetes and overweight or obesity. At 48 weeks, the 24 mg group had a reported HbA1c reduction of 2.65 percentage points and body-weight reduction of 15.5%. These are sponsor-reported changes, not figures described here as placebo-adjusted treatment differences. Gastrointestinal events were common; the release reported adverse-event discontinuation of 2% across enicepatide groups and 0% on placebo.

The result adds diabetes-population evidence to the development history. It cannot be ranked directly against a longer obesity trial excluding diabetes, and it does not settle long-term safety or cardiovascular outcomes. Roche identified additional glycemic and cardiovascular trials as planned for the first half of 2027.

The ENITH Phase 3 records distinguish participants with and without type 2 diabetes, use placebo control, and assess weight change at 72 weeks. Both records were recruiting when retrieved. These prospective designs explain what the next development stage is intended to establish; recruitment status alone says nothing about the outcome.

Roche acquired the program through Carmot. Its partnership with Zealand also creates a combination path involving petrelintide. The combination trial retains two compound identities, rather than inventing a new name for either constituent.

The competitive setting includes approved incretin treatments and other investigational mechanisms. Results from a diabetes population over 48 weeks should not be ranked directly against longer trials excluding diabetes. Current evidence also leaves longer-term tolerability and outcome questions.

Roche reported CHF 5.448 billion of cash and equivalents and CHF 4.286 billion of other marketable liquidity at June 30, a combined CHF 9.734 billion. Total debt was CHF 31.805 billion; the company's net-debt measure was CHF 22.071 billion. First-half operating cash flow was CHF 7.635 billion and IFRS net income CHF 7.325 billion. The profitable group can fund research from operating businesses, but these figures do not disclose a dedicated budget for either obesity program. Its CHF 4.197 billion free-cash-flow measure is distinct from operating cash flow.

Roche and Zealand’s collaboration was announced in March 2025 and became effective in May. Zealand received $1.4 billion upfront in the second quarter of 2025. A further $250 million is scheduled across two anniversaries; the first $125 million was received in the first half of 2026. Potential development and sales milestones total up to $1.2 billion and $2.4 billion respectively and remain contingent.

The partners share profits and losses equally in the United States and Europe, with co-commercialization rights. Roche has exclusive commercialization rights elsewhere, where Zealand is eligible for tiered double-digit royalties reaching the high teens. Roche carries commercial manufacturing investment responsibilities. The program includes petrelintide alone and combinations with Roche's enicepatide; the agreement's aggregate economics should not be assigned wholly to the combination or treated as cash reserved for a single trial.

Roche's December 2023 acquisition announcement identified CT-388 among several Carmot clinical programs. The announced consideration included an upfront purchase price and contingent milestones. That portfolio transaction should not be reported as a compound-specific research allocation. Current Roche releases identify CT-388 as enicepatide, while registry records also retain RO7795068. Keeping those names connected prevents an ownership change from appearing to create a new compound.